Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
BPC-157 and TB-500 are two of the most widely studied peptides in Canadian and US research settings, frequently explored in parallel because of their distinct but complementary roles in cellular signaling, cytoskeletal dynamics, and tissue-response pathways. This guide covers their mechanistic differences, molecular profiles, how they are studied individually and together, and what Canadian researchers need to know when sourcing either compound.
BPC-157 and TB-500 are distinct research peptides with different mechanisms and research applications. BPC-157 (CAS 137525-51-0) is a synthetic pentadecapeptide studied for angiogenic signaling, growth-factor pathways, and cellular-protection responses. TB-500 (CAS 77591-33-4) is a synthetic fragment of Thymosin Beta-4 studied for actin regulation, cell migration, and cytoskeletal organization. They are not interchangeable. They are often studied together because their mechanisms address different but related aspects of cellular and tissue biology.
BPC-157 is a synthetic pentadecapeptide based on a naturally occurring protective compound found in gastric tissue. Its full name is Body Protection Compound 157. Research interest centers on its interactions with angiogenic pathways, growth-factor signaling, vascular response models, and cellular protection cascades.
Its stability in lyophilized form and broad signaling interactions make it one of the most frequently used tools in in vitro and ex vivo system studies in preclinical peptide research.
BPC-157 is studied for its role in how cells signal each other to protect tissue, promote blood vessel formation, and regulate inflammatory responses. Research focuses on the signaling pathways themselves, not on clinical outcomes.
TB-500 is a synthetic peptide fragment of Thymosin Beta-4 (TB4), a protein involved in actin regulation, cell migration, and cytoskeletal organization. TB-500 isolates the TB4 region most associated with cell motility and structural modulation, making it a specific tool for mechanistic and cellular biology research.
Because it targets the actin-binding domain of Thymosin Beta-4, TB-500 is studied in models where cytoskeletal dynamics, tissue remodeling behavior, and cellular movement are the primary variables of interest.
TB-500 is studied for its role in how cells move and reorganize their internal structures. Research focuses on cytoskeletal architecture, actin polymerization, and cell migration, not on systemic outcomes.
BPC-157 and TB-500 have distinct molecular identities. Understanding their structural differences is foundational to understanding their different research applications.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Full name | Body Protection Compound 157 | Thymosin Beta-4 fragment (TB4 actin-binding domain) |
| Peptide type | Synthetic pentadecapeptide (15 amino acids) | Synthetic peptide fragment of Thymosin Beta-4 (17 amino acids) |
| CAS number | 137525-51-0 | 77591-33-4 |
| Biological origin | Derived from a gastric protective compound found naturally in gastric tissue | Fragment of Thymosin Beta-4, a protein naturally involved in actin regulation |
| Primary structural feature | 15-residue sequence with high stability and broad signaling interaction profile | Contains the actin-binding domain (LKKTETQ region) of Thymosin Beta-4 |
| Stability in lyophilized form | High; stable at standard lyophilized storage conditions | High; stable at standard lyophilized storage conditions |
BPC-157 and TB-500 operate through fundamentally different biological pathways. This is the most important distinction for research design.
| Mechanism Category | BPC-157 | TB-500 |
|---|---|---|
| Primary pathway | Angiogenic and growth-factor signaling; cellular protection cascades | Actin regulation; cytoskeletal organization; cell migration |
| Receptor interactions | Studied for interactions with VEGFR2 and growth hormone receptor pathways in preclinical models | Studied for interaction with G-actin sequestration, modulating actin polymerization dynamics |
| Cellular function focus | Vascular signaling, cellular protection, inflammatory modulation, angiogenesis-linked pathways | Cell motility, cytoskeletal reorganization, tissue-remodeling behavior |
| Biological category | Signaling and protection peptide | Structural and motility peptide |
| Inflammatory signaling | Studied in anti-inflammatory and cellular-protection models | Less direct involvement in inflammatory signaling; primarily structural |
| Vascular biology | Frequently studied in angiogenesis and VEGF-related pathway research | Some involvement in vascular cell migration models through actin dynamics |
Published preclinical literature covers each compound in distinct experimental contexts. The following summarizes the core research domains for each.
The following is the most complete head-to-head comparison of BPC-157 and TB-500 available for research reference purposes.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| CAS number | 137525-51-0 | 77591-33-4 |
| Amino acid length | 15 amino acids (pentadecapeptide) | 17 amino acids (TB4 fragment) |
| Biological origin | Derived from gastric protective compound | Fragment of Thymosin Beta-4 |
| Primary mechanism | Angiogenic and growth-factor signaling; cellular protection | Actin sequestration; cytoskeletal organization; cell migration |
| Biological category | Signaling and protection peptide | Structural and motility peptide |
| Primary receptor interaction | VEGFR2 and growth hormone receptor pathways (studied in preclinical models) | G-actin binding domain; actin polymerization dynamics |
| Angiogenesis research | Central focus; VEGF pathway interactions documented in multiple studies | Indirect involvement through vascular cell migration |
| Actin regulation | Not a primary mechanism | Central focus; G-actin sequestration studied extensively |
| Cell migration research | Studied via growth-factor pathways | Primary research focus through cytoskeletal dynamics |
| Inflammatory signaling | Studied in anti-inflammatory and protection models | Not a primary mechanism |
| Gastrointestinal research | Studied extensively due to gastric origin | Not a primary research area |
| Stability (lyophilized) | High | High |
| Storage (lyophilized) | -20°C | -20°C |
| Post-reconstitution storage | 2-8°C | 2-8°C |
| Luxara Labs purity | ≥99% (third-party HPLC + MS) | ≥99% (third-party HPLC + MS) |
Despite their mechanistic differences, BPC-157 and TB-500 are frequently studied in the same research programs. Understanding why requires understanding what each compound contributes independently.
| Research Rationale | BPC-157 Contribution | TB-500 Contribution |
|---|---|---|
| Dual-pathway modeling | Provides the signaling and vascular response dimension of tissue biology research | Provides the structural and motility dimension of tissue biology research |
| Complementary mechanisms | Addresses cellular communication, protection, and angiogenesis | Addresses cytoskeletal architecture, actin dynamics, and cell movement |
| Non-overlapping pathways | VEGFR2 and growth-factor signaling are distinct from actin regulation | Actin polymerization dynamics are distinct from angiogenic signaling |
| Research design benefit | Studying BPC-157 alone captures signaling events but not structural responses | Studying TB-500 alone captures structural events but not signaling responses |
| Combined study value | Studying both allows researchers to observe signaling and structural responses simultaneously in the same model, creating a more complete picture of tissue-level biology than either compound provides alone. | |
Both BPC-157 and TB-500 require the same storage conditions. Handling quality directly affects research data integrity.
| Handling Parameter | BPC-157 | TB-500 |
|---|---|---|
| Lyophilized storage | -20°C | -20°C |
| Post-reconstitution | 2-8°C; use within research window | 2-8°C; use within research window |
| Reconstitution agent | Bacteriostatic water is standard | Bacteriostatic water is standard |
| Freeze-thaw cycles | Minimize; each cycle degrades integrity | Minimize; each cycle degrades integrity |
| Environmental exposure | Avoid heat, direct light, and moisture | Avoid heat, direct light, and moisture |
| Purity requirement | ≥99% with third-party HPLC and MS verification | ≥99% with third-party HPLC and MS verification |
These pages extend the research context around BPC-157, TB-500, and related compounds.
These answers address the most common research questions about BPC-157 and TB-500 from Canadian and US researchers in 2026.
BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protective compound, studied for angiogenic signaling, growth-factor pathways, and cellular protection. TB-500 is a 17-amino-acid synthetic fragment of Thymosin Beta-4, studied for actin regulation, cell migration, and cytoskeletal organization. They operate through different mechanisms and are not interchangeable. BPC-157 is a signaling peptide; TB-500 is a structural and motility peptide.
Yes. In preclinical research settings, BPC-157 and TB-500 are frequently studied together because their mechanisms are complementary rather than overlapping. BPC-157 addresses the signaling and vascular response dimension of tissue biology. TB-500 addresses the structural and motility dimension. Studying both allows researchers to observe signaling and structural responses simultaneously in the same model. This is a research design choice, not a claim of synergy.
Both compounds should be stored lyophilized at -20°C prior to reconstitution. After reconstitution with bacteriostatic water, store at 2-8°C and use within the appropriate research window. Minimize freeze-thaw cycles, which degrade peptide integrity. Protect from heat, moisture, and direct light at all stages of handling. Both compounds are known for high stability in lyophilized form when stored correctly.
In preclinical research, BPC-157 has been studied in both localized and more systemic signaling contexts due to its gastric origin and broad pathway interactions. TB-500 is studied primarily in localized contexts related to cellular migration and cytoskeletal changes at specific tissue sites. Neither compound should be interpreted as producing confirmed systemic outcomes in human contexts based on current preclinical evidence.
Research-grade purity of 99% or above is required because any impurities in the peptide preparation become additional uncontrolled variables in the experimental model. When studying signaling pathways as specific as VEGFR2 interactions or actin polymerization dynamics, impurities can produce false signals, confound results, and make data unreproducible. Third-party HPLC and mass spectrometry verification are both required to confirm purity and compound identity independently.
Luxara Labs ships both compounds domestically across all Canadian provinces and territories and to all US states via express courier. Domestic Canadian shipments typically arrive within 1 to 3 business days. US shipments are also available with clear customs documentation. All products are shipped in lyophilized form in sealed, labeled vials with COA documentation available for every batch.
The following peer-reviewed publications support the mechanistic and molecular content discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
